The molecular characterization and clinical management of multiple myeloma in the post-genome era

od Zhou, Y, Barlogie, B, Shaughnessy, JD
Izdano 2009

Therapy-Related Myeloid Malignancies in Myeloma

od Papanikolaou, X., Barlogie, B., Usmani, S.Z.
Izdano 2011

High-dose cytosine arabinoside (Ara-C) in colorectal cancer.

od Kanojia, M., Kantarjian, H., Ajani, J., Barlogie, B.
Izdano 1983

A rare BclI RFLP in the putative oncogene bcI-1 locus

od Selvanayagam, P., Strong, L.C., Saunders, G.F., Barlogie, B.
Izdano 1990

Cytoplasmic immunoglobulin content in multiple myeloma.

od Barlogie, B, Alexanian, R, Pershouse, M, Smallwood, L, Smith, L
Izdano 1985

Light chain deposition disease derived from the kappa I light chain subgroup. Biochemical characterization.

od Picken, M. M., Frangione, B., Barlogie, B., Luna, M., Gallo, G.
Izdano 1989

Marrow cytometry and prognosis in myeloma.

od Barlogie, B, Alexanian, R, Gehan, E A, Smallwood, L, Smith, T, Drewinko, B
Izdano 1983

Nucleic acid cytometry of homosexual-associated lymphoproliferative disease.

od Srigley, J. R., Butler, J. J., Osborne, B. M., Guarda, L., Barlogie, B.
Izdano 1986

Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts

od Yaccoby, S, Pennisi, A, Li, X, Dillon, SR, Zhan, F, Barlogie, B, Shaughnessy, JD
Izdano 2007

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib

od Atrash, S, Tullos, A, Panozzo, S, Bhutani, M, Van Rhee, F, Barlogie, B, Usmani, S Z
Izdano u Blood Cancer J (2015)

Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances...

od Papanikolaou, X, Rosenbaum, ER, Tyler, LN, Sawyer, J, Heuck, CJ, Barlogie, B, Cottler-Fox, M
Izdano 2013

Vertebral augmentation in the treatment of pathologic compression fractures in 792 patients with multiple myeloma

od Erdem, E, Samant, R, Malak, S F, Culp, W C, Brown, A, Peterson, L, Lensing, S, Barlogie, B
Izdano 2013

Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16.

od Hoover, R G, Lary, C, Page, R, Travis, P, Owens, R, Flick, J, Kornbluth, J, Barlogie, B
Izdano 1995

Diagnostic Usefulness and Prognostic Impact of CD200 Expression in Lymphoid Malignancies and Plasma Cell Myeloma

od Alapat., D., Coviello-Malle, J.M., Owens, R., Qu, P., Barlogie, B., Shaughnessy, J.D., Lorsbach, R.B.
Izdano 2012

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

od Usmani, SZ, Crowley, J, Hoering, A, Mitchell, A, Waheed, S, Nair, B, AlSayed, Y, vanRhee, F, Barlogie, B
Izdano 2012

Pretreatment of cytokinetics in acute myelogenous leukemia. Age-related prognostic implications.

od Kantarjian, H M, Barlogie, B, Keating, M J, Hall, R R, Smith, T L, McCredie, K B, Freireich, E J
Izdano 1985

Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells

od Bam, R, Venkateshaiah, S U, Khan, S, Ling, W, Randal, S S, Li, X, Zhang, Q, van Rhee, F, Barlogie, B, Epstein, J, Yaccoby, S
Izdano u Blood Cancer J (2014)

Suppression of abnormal karyotype predicts superior survival in multiple myeloma

od Arzoumanian, V, Hoering, A, Sawyer, J, van Rhee, F, Bailey, C, Gurley, J, Shaughnessy, JD, Anaissie, E, Crowley, J, Barlogie, B
Izdano 2008

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma

od Heuck, C J, Qu, P, van Rhee, F, Waheed, S, Usmani, S Z, Epstein, J, Zhang, Q, Edmondson, R, Hoering, A, Crowley, J, Barlogie, B
Izdano u Leukemia (2014)

VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma

od Pineda-Roman, M, Zangari, M, van Rhee, F, Anaissie, E, Szymonifka, J, Hoering, A, Petty, N, Crowley, J, Shaughnessy, J, Epstein, J, Barlogie, B
Izdano 2008